We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
An image displaying a Newsletter on tablet, laptop & mobile

To continue reading this article, sign up for FREE to

Technology Networks logo


Membership is FREE and provides you with instant access to email newsletters, digital publications, our full content catalogue & more...

Boston Therapeutics Elects Dr. Henry Esber to its Board of Directors

Read time: Less than a minute

Boston Therapeutics, Inc. has announced the election of Dr. Henry J. Esber to its Board of Directors, effective December 20, 2011.

"We are very pleased to have Dr. Esber join our Board of Directors," said David Platt, Ph.D., Chairman of the Board of Directors and Chief Executive Officer of Boston Therapeutics.

Platt continued, "Dr. Esber is a highly regarded executive with extensive drug development and business experience. His expertise is a great addition to the Board of Directors."

"I believe Boston Therapeutics offers the potential to be the leader in diabetes drug development," said Dr. Esber.

Dr. Esber continued, "I am excited to be a part of a team that has a business model which includes near term revenue through sales of over-the-counter products, such as SUGARDOWN™, while developing PAZ320 as a pharmaceutical candidate for management of post-meal blood glucose in diabetics."

Google News Preferred Source Add Technology Networks as a preferred Google source to see more of our trusted coverage.